Discover why Eli Lilly and Company is set for a strong 2024 with a robust pipeline, solid financials, and strategic growth ...

Retatrutide mimics the effects of naturally occurring gut hormones to improve metabolic health. Stimulating insulin release ...

Eli Lilly stock has advanced more than 200% over the past three ... Lilly expects data readouts this year from a phase 3 ...

The endorsement comes in light of recent pre-clinical findings published on March 14th, suggesting that Eli Lilly’s Retatrutide has significant potential in reducing tumor progression and cancer ...

Citi reiterated a Buy rating and $1,190 price target on Eli Lilly (LLY), saying the firm expects a positive read-through to the shares on FDA’s ...

Several individuals enrolled in a phase 3 trial for Eli Lilly's (NYSE:LLY) next-generation obesity drug, retatrutide, say that while they have seen incredible weight loss, the trial has also come ...

Eli Lilly is set to keep growing its revenue at ... Consider two of the company's leading candidates in weight loss: orforglipron and retatrutide. Both medicines are in phase 3 studies, but ...

What's considered excellent revenue growth depends on the industry. With that context in mind, consider that Eli Lilly's ...

The endorsement comes in light of recent pre-clinical findings published on March 14th, suggesting that Eli Lilly’s Retatrutide has significant potential in reducing tumor progression and cancer risk, ...